Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

Phase 2TerminatedNCT00332319

GlaxoSmithKline1 enrolled

Overview

This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry. Part B will assess the effect of repeat doses of GW679769 on the bladder nerve function. Part B will also assess the effects of the drug on overactive bladder symptoms using a three-day patient diary.

A randomized, double-blind, placebo-controlled study to evaluate the effects of GW679769 on Current Perception Threshold (CPT) following a single 150 mg dose (Part A) and to evaluate the effect of CPT and symptoms of overactive bladder following 28 days of repeat dosing with 120 mg GW679769 administered once daily (Part B) in patients with neurogenic bladder due to incomplete spinal cord injury

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Incontinence, Urinary and Urinary Bladder, Overactive Overactive Bladder

Interventions

GW679769DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion criteria: * Spinal cord injury patients with overactive bladder symptoms including urge incontinence, urgency, frequency and night-time urination but without bladder related pain. * The injury must be above S1-3 Exclusion criteria: * Spinal cord injury suffered within 6 months. * History of interstitial cystitis, radiation cystitis, pelvic irradiation, or myocardial infarction with 1 year prior to screening. * Pregnant or nursing females. * Patients who have had hypersensitivity to lidocaine. * Patients who are taking oral corticosteroids. * Patients with active peptic ulcer disease (PUD) and/or history of PUD of an unknown etiology.

Locations (3)

GSK Investigational Site

Long Beach, California, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Change in bladder nerve activity assessed by neurometry before and after a single dose of GW679769 and placebo (part A) and after 28 days of drug or placebo treatment (part B).

Secondary Outcomes

Improvement of OAB symptoms (incontinence, frequency of urination, reduction in urgency, decrease in night-time urination episodes).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.